Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
24.73 USD +4.37% Intraday chart for Dyne Therapeutics, Inc. +3.65% +85.94%
25/03 Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell MT
25/03 Dyne Therapeutics, Inc. Announces Management Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
GL
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
GL
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell
MT
Dyne Therapeutics Announces CEO Transition
GL
Dyne Therapeutics, Inc. Announces Management Changes
CI
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes
CI
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
GL
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
AQ
Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating
MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating
MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating
MT
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing
MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating
MT
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell
MT
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GL
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
AQ
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing
MT
Dyne Therapeutics Insider Sold Shares Worth $811,865, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DYN Stock
  4. News Dyne Therapeutics, Inc.